Filing Overview
This Form 8-K was filed by Brilliant Acquisition Corporation, not T3 Defense Inc., with a report date of January 19, 2023 and subsequent events through January 25, 2023. Brilliant is a British Virgin Islands special purpose acquisition company (SPAC) pursuing a proposed business combination with Nukkleus Inc. The filing does not provide operating results for T3 Defense Inc.
Key Financial and Capitalization Information
- Shareholders redeemed 159,203 public ordinary shares in connection with the special meeting.
- Following the redemptions and trust-account contribution, approximately $4.4 million remained in the trust account.
- Brilliant reported 1,816,733 ordinary shares outstanding, including 1,411,000 shares held by initial shareholders and not subject to redemption.
- The reported pro rata trust-account value was approximately $10.77 per public share.
- Brilliant issued an unsecured, non-interest-bearing $21,350 promissory note to Nukkleus, maturing upon closing of the initial business combination. If no business combination occurs, repayment is limited to funds remaining outside the trust account, if any.
- The note proceeds were deposited into the trust account in connection with extending the business-combination deadline.
- The filing does not provide revenue, net income, cash-flow, operating-margin, or total-debt figures.
Material Changes and Transaction Developments
- Brilliant shareholders approved proposals to extend the business-combination deadline from January 23, 2023 to no later than April 23, 2023 and to adopt amended and restated articles of association.
- The amended articles permit monthly extensions, subject to additional deposits into the trust account, initially at $0.04 per public ordinary share.
- Brilliant stated that it would increase the monthly contribution to $0.0525 per outstanding ordinary share and subsequently committed to $0.08 per share for the February 23-to-March 23 and March 23-to-April 23 extension periods.
- Amendment No. 3 to the merger agreement extends the outside closing date to the later of April 23, 2023 or an approved SPAC-life extension date, but not later than June 23, 2023.
- The company announced a further one-month extension of its business-combination period to February 23, 2023.
Outlook, Risks, and Unusual Items
The proposed merger with Nukkleus remains subject to required shareholder approvals, satisfaction of minimum trust-account conditions after redemptions, regulatory approvals, and other closing conditions. The transaction may not be completed by the applicable deadline or at all.
Key disclosed risks include additional shareholder redemptions, failure to obtain further deadline extensions, failure to maintain Nasdaq listing, legal or regulatory proceedings, disruption to Nukkleus’s operations and employee retention, changes in regulation and market conditions, and the ability of the combined company to implement its business plans. The filing states that the proposed transaction is not an offer or solicitation and directs investors to the relevant Form S-4, proxy statement/prospectus, and other SEC filings.
Investor Verification Checklist
- Verify the identity of the registrant and whether this filing is relevant to T3 Defense Inc.; the filing names Brilliant Acquisition Corporation and Nukkleus Inc.
- Review the complete merger agreement and Amendment No. 3 for closing conditions, termination rights, and the revised outside closing date.
- Confirm the final number of shares redeemed, trust-account balance, per-share trust value, and extension contributions.
- Assess whether additional extensions or the proposed business combination were subsequently approved and completed.
- Review the Form S-4, definitive proxy materials, and subsequent SEC filings for dilution, minimum-cash requirements, regulatory approvals, and updated transaction terms.